Lexicon Pharmaceuticals | LXRX - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Abbott USD 5.86B 675M 2026-03
Acadia Pharmaceuticals USD 243.27M 14.49M 2026-03
Agios Pharmaceuticals USD 19.43M 1.34M 2026-03
Akebia Therapeutics USD 47.28M 1.7M 2025-12
Alnylam Pharmaceuticals USD 825M 4.3M 2026-03
AstraZeneca USD 12.61B 225M 2026-03
BioMarin Pharmaceutical USD 571.21M 141.8M 2026-03
Coherus Biosciences USD 8.7M 853K 2025-12
Eli Lilly USD 15.92B 1.33B 2025-12
Esperion Therapeutics USD 140.59M 94.57M 2025-12
Halozyme Therapeutics USD 297.47M 75.53M 2026-03
Illumina USD 721M 38M 2026-03
Insmed USD 256.46M 38.78M 2026-03
Ironwood Pharmaceuticals USD 85.24M 44.1M 2025-06
J&J USD 17.24B 642M 2026-03
Lexicon Pharmaceuticals USD 5.29M 8.88M 2025-12
MacroGenics USD 31.11M 30.14M 2025-12
MannKind USD 68.33M 9.98M 2026-03
Merck USD 10.85B 2.57B 2025-12
Moderna USD -566M 792M 2026-03
Novartis USD 10.07B 184M 2026-03
PTC Therapeutics USD 232.94M 84.56M 2026-03
Puma Biotechnology USD 20.32M 24.85M 2024-09
Sarepta Therapeutics USD 621.34M 577.79M 2026-03
Thermo Fisher Scientific USD 4.49B 146M 2026-03
Ultragenyx Pharmaceutical USD 106M 72M 2026-03
United Therapeutics USD 315.5M 286.6M 2025-12
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12